Skip to main content
. Author manuscript; available in PMC: 2019 May 6.
Published in final edited form as: Oncogene. 2018 Nov 6;38(12):2056–2075. doi: 10.1038/s41388-018-0543-2

Figure 3. Pharmacological inhibition of the ACVR1C/SMAD2 pathway using SB505124 represses growth and invasion in retinoblastoma cells.

Figure 3.

a, c, e: Growth was inhibited in a dose-dependent manner in WERI Rb1 (a), Y79 (c), and HSJD-RBVS-10 (e) cells treated with SB505124 for 3, 5, 7 days at the indicated doses, as found by CCK-8 assay. P values were calculated using two-sided Student t-test vs DMSO-treated cells. Data are presented as the mean + SD. b, d, f: The ability of the cells to invade a Matrigel-coated filter was reduced in a dose-dependent manner in WERI Rb1 (b), Y79 (d), and HSJD-RBVS-10 (f) cells treated with SB505124 for 3 days at the indicated doses, as found by transwell invasion assay.